In which countries is Serputinib/Serpatinib produced and sold?

Selpercatinib is a drug that targets RET gene mutations and is mainly used to treat advanced non-small cell lung cancer (NSCLC), thyroid cancer and other related cancers with RET gene mutations. It achieves anti-cancer effects by inhibiting RET receptor tyrosine kinase and blocking RET-related cancer cell proliferation signals. Seputinib was approved by the US FDA in 2020 for the treatment of patients with RET fusion-positive or RET-mutated advanced non-small cell lung cancer. In 2021, it also received approval to treat thyroid cancer with RET mutations.

The clinical application of Seputinib is mainly concentrated in patients with non-small cell lung cancer and thyroid cancer, especially those who have received traditional treatments such as chemotherapy and immunotherapy. The drug has significant therapeutic effects on patients with RET gene mutations or RET gene fusions. Studies have shown that seputinib can significantly improve the survival and quality of life of these patients.

Regarding production and sales, the original drug of Seputinib is produced and sold by Eli Lilly Company in the United States. It was first approved in the U.S. and subsequently entered multiple international markets. The European Union, Canada, Japan, South Korea and other places have approved the marketing of seputinib. In these countries, seputinib is mainly used to treat advanced non-small cell lung cancer with RET gene mutations and thyroid cancer with RET mutations. The launch progress of different countries may vary, but in general, the market of seputinib is gradually expanding, especially among cancer patients who require specific targeted therapies, and is gradually gaining recognition.

In addition, the production and sales of Seputinib are expanding to other regions, including China and other countries. The launch in the Chinese market has progressed relatively slowly. Although it has been approved, it has not yet been included in medical insurance, and the price is relatively high, limiting patient accessibility. However, as market demand increases and the policy environment changes, there may be more sales channels and indication approvals in the future. Major pharmaceutical companies around the world are also promoting the development of similar targeted therapies in order to provide more treatment options for patients with RET gene mutations.

Reference:https://en.wikipedia.org/wiki/Selpercatinib